FDA approves a new type of schizophrenia drug
FDA Approves New Kind of Drug for Schizophrenia
FRIDAY, Sept. 27, 2024 (HealthDay News) -- The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and Drug Administration.
FDA approves 1st new drug to treat schizophrenia in more than 30 years
This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a new alternative to the antipsychotic medications peo
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades.
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna Therapeutics.
This FDA-approved drug promises a new way to treat schizophrenia
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments
Revolutionary drug for schizophrenia wins US approval
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom relief with fewer side effects.
FDA eyes first schizophrenia drug shift in decades
The Food and Drug Administration is slated to decide Thursday whether to approve the first new schizophrenia drug in at least three decades. Why it matters: The complex condition is currently treated with antipsychotics that carry safety risks like metabolic disorders,
The FDA is expected to approve a new type of schizophrenia drug
The Food and Drug Administration is expected to approve KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
The FDA approves a new type of schizophrenia drug
The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
FDA eyes 1st schizophrenia drug in decades: 5 things to know
The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating schizophrenia in decades,
FDA, Esta and Labs
FDA Lifts Clinical Hold On BMF-219
Severity of various FDA product recalls including Class I which can cause death, serious illness
Hundreds of foods are recalled by the FDA every year. Food recalls could fall into different categories, depending on how ...
Establishment Labs Jumps In Pre-market On FDA Approval Of Its Motiva Breast Implants
Shares of Establishment Labs Holdings Inc. (ESTA) were surging more than 21 percent in pre-market on Friday to $50.22, after its ...
Scones Recall Update As FDA Sets Risk Level
Batches of Blueberry and Marionberry Scones have been recalled because of undeclared soy lecithin and soybean oil on the ...
FDA’s views on AI are evolving
The guidance is based in part on responses the agency received to a 2023 discussion paper on the topic. The paper received ...
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful ...
FDA approves new schizophrenia drug
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
STAT1d
FDA introduces plan to assess safety of common chemicals added to food
SILVER SPRING, Md. — Food additives rarely face FDA scrutiny once they’re on the market, even those with mounting evidence ...
studyfinds1d
Alzheimer’s drug breakthrough or breakdown? Investigation exposes red flags in FDA approval of donanemab
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...